Jazz Pharmaceuticals Management
Management criteria checks 3/4
Jazz Pharmaceuticals' CEO is Renee Gala, appointed in Oct 2023, has a tenure of 2.25 years. total yearly compensation is $6.63M, comprised of 12.4% salary and 87.6% bonuses, including company stock and options. directly owns 0.049% of the company’s shares, worth $4.97M. The average tenure of the management team and the board of directors is 6.4 years and 9.8 years respectively.
Key information
Renee Gala
Chief executive officer
US$6.6m
Total compensation
| CEO salary percentage | 12.44% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.05% |
| Management average tenure | 6.4yrs |
| Board average tenure | 9.8yrs |
Recent management updates
Recent updates
Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified
Nov 18
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise
Nov 17Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 09Lacklustre Performance Is Driving Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Low P/E
Jul 21Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly
Jul 03Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts
May 09Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Deserve A Spot On Your Watchlist?
Apr 27Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Apr 09Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly
Feb 22With EPS Growth And More, Jazz Pharmaceuticals (NASDAQ:JAZZ) Makes An Interesting Case
Jan 12Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
Dec 23Jazz Pharmaceuticals: High Uncertainty, Low Risk
Nov 18Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
Oct 16Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
Sep 19
Xywav And Epidiolex Drive Market Penetration And Promise Robust Revenue Growth Amid Strategic Shifts And Innovation Focus
Strategic diversification and investments in R&D aim to reduce reliance on the oxybate franchise, focusing on oncology and Epidiolex for future growth.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$368m |
| Jun 30 2025 | n/a | n/a | -US$405m |
| Mar 31 2025 | n/a | n/a | US$482m |
| Dec 31 2024 | US$7m | US$825k | US$560m |
| Sep 30 2024 | n/a | n/a | US$463m |
| Jun 30 2024 | n/a | n/a | US$395m |
| Mar 31 2024 | n/a | n/a | US$331m |
| Dec 31 2023 | US$5m | US$768k | US$415m |
| Sep 30 2023 | n/a | n/a | US$80m |
| Jun 30 2023 | n/a | n/a | -US$87m |
| Mar 31 2023 | n/a | n/a | -US$156m |
| Dec 31 2022 | US$5m | US$690k | -US$224m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$52m |
| Mar 31 2022 | n/a | n/a | -US$450m |
| Dec 31 2021 | US$5m | US$617k | -US$330m |
| Sep 30 2021 | n/a | n/a | -US$161m |
| Jun 30 2021 | n/a | n/a | US$40m |
| Mar 31 2021 | n/a | n/a | US$518m |
| Dec 31 2020 | US$4m | US$485k | US$239m |
Compensation vs Market: Renee's total compensation ($USD6.63M) is below average for companies of similar size in the US market ($USD13.27M).
Compensation vs Earnings: Renee's compensation has increased whilst the company is unprofitable.
CEO
Renee Gala (53 yo)
Ms. Ren e D. Gal? is an Independent Director of DexCom, Inc. from March 6, 2025.She serves as President at Jazz Pharmaceuticals plc since October 2023 and served as Chief Operating Officer at Jazz Pharmac...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 23yrs | US$15.53m | 0.48% $ 48.4m | |
| President | 2.3yrs | US$6.63m | 0.049% $ 5.0m | |
| Executive VP & CFO | 1.8yrs | US$5.24m | 0.025% $ 2.5m | |
| Senior VP & Chief Accounting Officer | 6.4yrs | US$1.45m | 0% $ 0 | |
| Executive VP | 6.7yrs | US$5.69m | 0.040% $ 4.1m | |
| Executive VP & Chief Commercial Officer | 5.8yrs | US$4.46m | 0.018% $ 1.9m | |
| Executive Director of Investor Relations | no data | no data | no data | |
| Executive VP & Chief Legal Officer | 6.5yrs | US$3.88m | 0.021% $ 2.2m | |
| Executive VP & Chief People Officer | 7.2yrs | no data | no data | |
| Senior Vice President of Sleep & CNS Medicine | no data | no data | no data | |
| Senior Vice President of Corporate Strategy | 6.3yrs | no data | no data | |
| Senior Vice President of Technical Operations | 2.4yrs | no data | 0.0016% $ 166.4k |
Experienced Management: JAZZ's management team is seasoned and experienced (6.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 23yrs | US$15.53m | 0.48% $ 48.4m | |
| President | less than a year | US$6.63m | 0.049% $ 5.0m | |
| Independent Director | 14yrs | US$530.07k | 2.1% $ 213.4m | |
| Independent Director | 12.7yrs | US$533.18k | 0.023% $ 2.4m | |
| Independent Director | 16.5yrs | US$525.07k | 0.038% $ 3.8m | |
| Independent Director | 1.8yrs | US$675.39k | 0.0053% $ 533.7k | |
| Lead Independent Director | 15.7yrs | US$570.07k | 0.0089% $ 899.0k | |
| Independent Non-Executive Director | 5.1yrs | US$534.27k | 0.012% $ 1.2m | |
| Independent Director | 1.5yrs | US$460.60k | 0.0056% $ 572.3k | |
| Independent Director | 12.7yrs | US$542.57k | 0.028% $ 2.8m | |
| Independent Non-Executive Director | 5.1yrs | US$520.07k | 0.012% $ 1.2m | |
| Independent Director | 6.9yrs | US$523.66k | 0.021% $ 2.2m |
Experienced Board: JAZZ's board of directors are considered experienced (9.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/07 05:32 |
| End of Day Share Price | 2026/01/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jazz Pharmaceuticals plc is covered by 45 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Brian Skorney | Baird |
| null null | Baird |